Herpes simplex viruses type 1 and 2 (HSV-1, HSV-2) cause genital herpes (GH). GH is medically significant as a co-factor for HlV-1 transmission and progression and results in considerable physical and psychological pain and suffering. Long-term, an effective preventative vaccine w/ill be required to reduce the burden of HSV-1 and HSV-2. Recent trials of adjuvanted subunit vaccines eliciting antibody and CD4 responses but not CDS responses failed to protect against HSV-2 infection or disease. Additionally, an immunotherapeutic vaccine for GH would be a valuable addition to licensed drugs. Recent data from our lab and other groups indicate that HSV-specific CDS T-cells localize and persist at sites of HSV infection suggesting that they prevent peripheral viral replication and thus may modulate primary and recurrent infection.
In Aim 1 we will enroll immunocompetent persons with mild or severe HSV-2 infection phenotypes, as defined by both clinical and HSV shedding criteria, and perform systematic studies of circulating CDS T-cell responses. Our methods provide high definition data concerning abundance, fine specificity and phenotypes of HSV-2- specific cells. Differences in target antigens specific for persons with mild infection may provide vaccine candidates that can elicit protective CDS T-cells. To study localization of CDS T-cells to the genital tract in asymptomatic persons, we will enroll women and in Aim 2 use T-cell receptor (TCR) hypervariable gene sequences as the signature of HSV-2-specific T-cells to study the localization of HSV-2-specific CDS T-cells in the cervix.
These Aim 2 TCR assays will be coordinated with Project 3 which studies skin-resident HSV-2- specific CDS T-cells. Primary genital HSV-1 infection is an emerging problem. In coordination with Project 4, Aim 3 of this Project will measure the dynamics of the T-cell response to primary genital HSV-1 infection. Assays for both CD4 and CDS responses will test if continuous priming of HSV-specific T-cells occurs during the first year following resolution of primary infection. This is important with regards to the possibility of therapeutic vaccination. The kinetics of acquistion of the profound skin homing program of HSV-1-specific CDS T-cells will also be defined.

Public Health Relevance

Understanding of the immune response to herpes simplex types 1 and 2 is an important component of making a vaccine. This Project will determine if a portion of the immune response termed CDS T-cells is correlated with genital herpes severity, and will also study the localization of these immune cells to infected tissues and the development of immunity in persons with new infections. PROJECT/PERFORIVIANCE SITE(S) (if additional space is needed, use Project/

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI030731-23
Application #
8565776
Study Section
Special Emphasis Panel (ZAI1-LR-M (M1))
Project Start
Project End
Budget Start
2013-07-05
Budget End
2014-06-30
Support Year
23
Fiscal Year
2013
Total Cost
$278,008
Indirect Cost
$84,408
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Schiffer, Joshua T; Swan, Dave A; Roychoudhury, Pavitra et al. (2018) A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection. J Immunol 201:1522-1535
Traidl, Stephan; Kienlin, Petra; Begemann, Gabriele et al. (2018) Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses. J Allergy Clin Immunol 141:1144-1147.e5
Ramchandani, Meena; Selke, Stacy; Magaret, Amalia et al. (2018) Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. Sex Transm Infect 94:568-570
Boucoiran, Isabelle; Mayer, Bryan T; Krantz, Elizabeth M et al. (2018) Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. Pediatr Infect Dis J 37:627-631
Kleinstein, Sarah E; Shea, Patrick R; Allen, Andrew S et al. (2018) Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2). Genes Immun :
Posavad, C M; Zhao, L; Dong, L et al. (2017) Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. Mucosal Immunol 10:1259-1269
Johnston, Christine; Magaret, Amalia; Roychoudhury, Pavitra et al. (2017) Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. PLoS Med 14:e1002475
Matrajt, Laura; Gantt, Soren; Mayer, Bryan T et al. (2017) Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. Sci Rep 7:13105
Hensel, Michael T; Peng, Tao; Cheng, Anqi et al. (2017) Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells. J Virol 91:
Gilbert, Peter B; Excler, Jean-Louis; Tomaras, Georgia D et al. (2017) Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One 12:e0176428

Showing the most recent 10 out of 345 publications